Peptide therapeutics, due to their various advantages such as high stability, selectivity, safety, efficacy, bioavailability, and tolerability offers wide applications over the other therapeutics classes. Over 7,000 naturally occurring peptides have been identified, which have crucial roles in human physiology, which include hormones, neurotransmitters, growth factors, ion channel, and ligands. The structure of these peptides is usually complex and these conformations depending upon their environment.

Manufacturers are focusing on developments in biologics and biopharmaceutical peptides and proteins for application in diagnostics and therapies. According to the data published in Drug Discovery Today, in January 2015, around 140 peptide therapeutics are currently evaluated in clinical trials. Peptide therapeutics are increasingly been used for therapeutics in metabolic diseases and oncology. Rising incidence of metabolic diseases such as Diabetes mellitus type 2 (T2DM) and Obesity are expected to be factors driving growth of the market. According to World Health Organization (WHO) 2017 data findings, the number people suffering from diabetes have increased from 108 million to 422 million in 2014. Similarly, the world obesity rate has increased three times since 1975 and in 2016, over 1.9 billion adults (18 year and above) were estimated to be overweight. Moreover, high incidence rate of metabolic disorders is expected to propel growth of peptide therapeutics in metabolic disorders market in the near future. According to the Centers for Disease Control and Prevention (CDC) October 2017 data findings, in 2011–2012, 78 million U.S. adults had low-density lipoprotein cholesterol levels, which put them at high risk of heart disease and stroke. However, high prices of products is expected to negatively impact the overall market growth.

Among the metabolic disorders, the risk of developing type 1 and type 2 diabetes is related to the combination of variants in multiple genes. In rare cases, patients which are monogenic having single gene mutation which can lead to diabetes. The first peptide to be administrated therapeutically was insulin and has been used in the treatment of diabetes. Development of novel analogues such as lispro insulin that is an injection to be taken prior to meal, has also aided in growth of the market. Another important peptide is glucagon like peptide-1 (GLP-1), which has insulin-releasing properties and also helps to suppress the glucagon level. The glucose dependent action of GLP-1 is more potent to regulate glucose level after a meal. These properties of peptides has aided in development of novel therapeutics and is expected to drive growth of the market in the near future. According to the data published in the January 2015, in Drug Discovery Today Journal, total 60 peptides-based drugs such as viscozyme, pulmozyme, glucagen are available in the market and number of other therapeutic peptides such as cpd86 (preclinical), MOD-6030 (preclinical), MAR709 (II) and semaglutide (III) are currently evaluated in different phase of clinical trial thus, strong pipeline is expected to propel growth of the peptide therapeutics in metabolic disorders market in the near future.

Collaborations and new product launches:

Key players in the market are focusing on collaborations and new product launches, in order to enhance their market share. For instance, Rhythm Pharmaceuticals Inc. is engaged in developing obesity drug called setmelanotide a Melanocortin 4 receptor (MC4R) agonist peptide that is meant to be injected daily to regulate the body energy balance and appetite. Moreover, in June 2017, Rhythm Pharmaceuticals and Camurus AB released the positive initial results from ongoing Phase 1A clinical trial, which evaluated the pharmacokinetics and tolerability of an extended-release formulation of setmelanotide. The company is also conducting trials for the treatment of extremely rare metabolic disorders such as Pro-opiomelanocortin (POMC) and Leptin receptor (LepR) deficiency obesity. Furthermore, in September, 2017, Zealand Pharma and Torrey Pines Institute for Molecular Studies entered into a research collaboration for multi-target research to identify novel peptide-based products by using Torrey Pines Institute for Molecular Studies (TPIMS’s) peptide libraries. This collaboration will help to develop specialty medicines to treat metabolic and gastrointestinal diseases.     

Key players in the Peptide Therapeutics in Metabolic Disorders Market:

Some of the key players operating in the market are AstraZeneca plc, F. Hoffmann-La Roche Ltd, Sanofi S.A., Teva Pharmaceutical Industries Ltd., PolyPeptide Group, Eli Lilly and Company, Bachem Holding AG, Takeda Pharmaceuticals Co. Ltd., Ipsen S.A, Rhythm Pharmaceuticals Inc., and Novo Nordisk A/S.

Global Peptide Therapeutics in Metabolic Disorders Market Taxonomy

On the basis of route of administration, peptide therapeutics in metabolic disorders market is segmented into:

  • Intravenous
  • Oral
  • Nasal
  • Others

On the basis of synthesis technology, peptide therapeutics in metabolic disorders market is segmented into:

  • Solid Phase Peptide Synthesis
  • Liquid Phase Peptide Synthesis
  • Hybrid Technology

On the basis of distribution channels, peptide therapeutics in metabolic disorders market is segmented into:

  • Hospitals
  • Specialty Clinics
  • Retail Pharmacy
  • Online Pharmacy

Research Methodology

Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:

  • Primary Research (Trade Surveys and Experts Interviews)
  • Desk Research
  • Proprietor Data Analytics Model

In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.

Data Triangulation Methodology | Coherent Market Insights

Coherent Market Insights desk research is based on a principle set of research techniques:

  • National level desk research: It Includes research analysis of regional players, regional regulatory bodies, regional trade associations, and regional organization.
  • Multinational level desk research: The research team keeps a track of multinational players, global regulatory bodies, global trade associations, and global organization.

Coherent Market Insights has a large amount of in-house repository of industry database. This is leveraged as a burner for initiating a new research study. Key secondary sources include:

  • Governmental bodies, National and international social welfare institutions, and organizations creating economic policies among others.
  • Trade association, National and international media and trade press.
  • Company Annual reports, SEC filings, Corporate Presentations, press release, news, and specification sheet of manufacturers, system integrators, brick and mortar - distributors and retailers, and third party online commerce players.
  • Scientific journals, and other technical magazines and whitepapers.

Market Analysis | Coherent Market Insights

Preliminary Data Mining

The raw data is obtained through the secondary findings, in house repositories, and trade surveys. It is then filtered to ensure that the relevant information including industry dynamics, trends, and outlook is retained for further research process.

Data Standardization

Holistic approach is used to ensure that the granular and uncommon parameters are taken into consideration to ensure accurate results. The information from the paid databases are further combined to the raw data in order to standardize it.

Coherent Statistical model

We arrive at our final research findings through simulation models. Coherent Data Analytics Model is a statistical tool that helps company to forecast market estimates. Few of the parameters considered as a part of the statistical model include:

  • Micro-economic indicators
  • Macro-economic indicators
  • Environmental indicators
  • Socio-political indicators
  • Technology indicators

Data Processing

Once the findings are derived from the statistical model, large volume of data is process to confirm accurate research results. Data analytics and processing tools are adopted to process large chunk of collected informative data. In case, a client customizes the study during the process, the research finding till then are benchmarked, and the process for new research requirement is initiated again.

Data Validation

This is the most crucial stage of the research process. Primary Interviews are conducted to validate the data and analysis. This helps in achieving the following purposes:

  • It provides first-hand information on the market dynamics, outlook, and growth parameters.
  • Industry experts validates the estimates which helps the company to cement the on-going research study.
  • Primary research includes online surveys, face-to face interviews, and telephonic interviews.

The primary research is conducted with the ecosystem players including, but not limited to:

  • Raw Material Suppliers
  • Manufacturers
  • System Integrators
  • Distributors
  • End-users